Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.44 |
| ▸ | CNR1 | P21554 | 9/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.32 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23721937 | 0.99 | CNR2 (0.43) | CNR2CNR1KDM1APFKFB2PFKFB1 | |
| SCHEMBL23721908 | 0.92 | CNR2 (0.44) | CNR2CNR1KDM1APFKFB2PFKFB1 | |
| SCHEMBL23745349 | 0.88 | CNR2 (0.39) | CNR2CNR1ICMT | |
| SCHEMBL23721947 | 0.88 | CNR2 (0.39) | CNR2CNR1ICMT | |
| Hydrochloric Acid SCHEMBL23722140 | 0.87 | CNR2 (0.38) | CNR2CNR1ICMT | |
| SCHEMBL23722038 | 0.86 | SOS1 (0.41) | CNR2CNR1KDM1AICMTMCHR1 | |
| SCHEMBL23745522 | 0.86 | CNR2 (0.44) | CNR2CNR1KDM1APFKFB2PFKFB1 | |
| Hydrochloric Acid SCHEMBL23722112 | 0.85 | CNR2 (0.44) | CNR2CNR1KDM1APFKFB2PFKFB1 | |
| SCHEMBL22439462 | 0.81 | CNR2 (0.55) | CNR2CNR1PFKFB2PFKFB1PFKFB3 | |
| SCHEMBL23745604 | 0.81 | CNR2 (0.42) | CNR2CNR1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | CNR2 2528/4885CNR1 1651/4885KDM1A 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.